NCT00893139
Completed
Phase 2
A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye
ConditionsDry Eye
Overview
- Phase
- Phase 2
- Intervention
- AL-38583 ophthalmic solution 0.05%
- Conditions
- Dry Eye
- Sponsor
- Alcon Research
- Enrollment
- 765
- Primary Endpoint
- Mean change from baseline in sodium fluorescein corneal staining score
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The purpose of this study is to determine whether AL-38583 ophthalmic solution is effective for treatment of signs and symptoms of dry eye.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Composite corneal staining score of greater than 5 in one or both eyes.
- •Schirmer II score of greater than 4 mm.
- •OSDI score of greater than
- •Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
- •Any medical condition (systemic or ophthalmic) that may, in the opinion of the investigator, preclude the safe administration of the test article or safe participation in this study.
- •Other protocol-defined exclusion criteria may apply.
Arms & Interventions
AL-38583 0.05%
AL-38583 ophthalmic solution 0.05%, 1 drop per eye, 3 times a day, for 35 days
Intervention: AL-38583 ophthalmic solution 0.05%
AL-38583 0.10%
AL-38583 ophthalmic solution 0.10%, 1 drop per eye, 3 times a day, for 35 days
Intervention: AL-38583 ophthalmic solution 0.10%
AL-38583 vehicle
Inactive ingredients used as a placebo comparator, 1 drop per eye, 3 times a day, for 35 days
Intervention: AL-38583 vehicle
Outcomes
Primary Outcomes
Mean change from baseline in sodium fluorescein corneal staining score
Time Frame: Baseline, up to Day 35
Secondary Outcomes
- Mean change from baseline in phenol red thread length(Baseline, up to Day 35)
Similar Trials
Withdrawn
Phase 2
To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen ChallengeAllergic ConjunctivitisNCT00881673Alcon Research
Completed
Phase 2
AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated InflammationAllergic ConjunctivitisNCT01001091Alcon Research312
Completed
Phase 3
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye DiseaseDry Eye DiseaseNCT06544694Alcon Research79
Terminated
Phase 3
Geographic Atrophy Treatment EvaluationGeographic AtrophyAge-Related Macular DegenerationNCT00890097Alcon Research772
Completed
Phase 3
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic ConjunctivitisAllergic ConjunctivitisNCT01743027Alcon Research902